<DOC>
	<DOCNO>NCT01117506</DOCNO>
	<brief_summary>To validate use Corus™ CAD blood assay subject refer work-up coronary artery disease . The study evaluate clinical utility gene expression test ( Corus CAD ) subject referred myocardial perfusion imaging ( MPI ) work-up suspect obstructive atherosclerotic coronary artery disease ( CAD ) . The Corus CAD gene expression test quantify expression multiple gene circulate peripheral blood cell detect presence clinically significant obstructive CAD patient chest pain .</brief_summary>
	<brief_title>Coronary Obstruction Detection Molecular Personalized Gene Expression</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Ages 4590 woman ; 3590 men . Stable chest pain syndrome ( typical atypical ) anginal equivalent judgment investigator ( e.g. , pain neck , jaw , arm shoulder dyspnea possibly due cardiac ischemia ) . Referred stress test use MPI . The patient sign appropriate Institutional Review Board approve Informed Consent Form . History known MI significant CAD . Current MI acute coronary syndrome . Current New York Heart Association ( NYHA ) class III IV congestive heart failure symptom . Severe regurgitant stenotic cardiac valvular lesion . Severe leave ventricular systolic dysfunction ( LVEF ≤ 35 % document last year ) ; assessment perform documented year precede enrollment , presume normal LVEF . Active systemic infection ( diagnosed combination clinical symptom laboratory testing , include limited fever , leukocytosis , positive blood culture , pneumonia , urinary tract infection , abscess precede 2 month ) chronic infection ( e.g. , HIV , Hepatitis B C , Tuberculosis ) . Protocolspecified rheumatologic , autoimmune hematologic condition ( e.g. , rheumatoid arthritis , systemic lupus erythematosis , polymyalgia rheumatica , systemic sarcoidosis ) . Known suspected diabetes mellitus document Hemoglobin A1c ( HbA1c ) ≥ 6.5 ; presume normal HbA1c none document . Total WBC ≥ 11,000 cells/ul platelet count ≤ 75,000 cells/ul CBC differential drawn within 7 day prior enrollment [ WBC ≥ 11,000 cells/ul platelet count ≤ 75,000 cells/ul CBC drawn &gt; 7 day prior need redrawn enrollment ] . Recipient organ transplant . Immunosuppressive immunomodulatory therapy include dose systemic corticosteroid precede 2 month . Chemotherapy precede year . Major surgery precede 2 month . Blood blood product transfusion precede 2 month . Subjects form ( stress pharmacologic ) MPI contraindicate . Subjects invasive coronary angiography coronary CT angiography contraindicate , include IV betablocker . Subjects plan decline research CCTA invasive coronary angiography , regardless MPI result . Subjects history atrial fibrillation/flutter frequent irregular rapid heart rhythm . Known history renal insufficiency ( serum creatinine ≥ 2.0 mg/dL ) , severe allergy iodinate contrast .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Angina</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Molecular Genetics</keyword>
	<keyword>Atherosclerosis</keyword>
</DOC>